116051 ⎘
Transferases transferring phosphorus-containing groups (2.7); Protein-tyrosine kinases (2.7.10) Receptor protein-tyrosine kinase (2.7.10.1)
GENE THERAPY FOR OCULAR DISEASE
#2TRANSGENIC ANIMALS EXPRESSING CHIMERIC C-KIT PROTEIN
#3COMPOSITIONS AND METHODS FOR MICROGLIA REPLACEMENT THERAPY
#4ANTI-EGFR/MET ANTIBODIES AND USES THEREOF
#5SWITCH RECEPTORS AND MODIFIED IMMUNE CELLS
#6EXPRESSION OF NOVEL CELL TAGS
#7REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS
#8REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS
#9MUSK-TARGETING OLIGONUCLEOTIDES
#10ANTI-EGFR ANTIBODIES, ANTI-CMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
#11ANTIGEN-SPECIFIC THERAPY FOR AUTOIMMUNE DISEASES
#12METHODS OF TREATING CHOLANGIOCARCINOMA
#13FULLY STABILIZED ASYMMETRIC SIRNA
#14EPITOPE ENGINEERING OF CELL-SURFACE RECEPTORS
#15GENETICALLY ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME
#16C-KIT ANTIBODIES
#17ANAPLASTIC LYMPHOMA KINASE (ALK) CANCER VACCINES AND METHODS OF USE THEREOF
#18Crenolanib for Treating FLT3 Mutated Proliferative Disorders
#19Crystal Structures of ALK and LTK Receptor Tyrosine Kinases and Their Ligands
#20METHODS AND COMPOSITIONS FOR TARGETING ALTERNATIVE METABOLISM ALONG WITH FLT3 INHIBITOR-MEDIATED ANTILEUKEMIC ACTIONS
#21VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME
#22TREATMENT OF MST1R RELATED DISEASES AND DISORDERS
#23Ligand Binding Molecules and Uses Thereof
#24MERTK PEPTIDES AND USES THEREOF
#25NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING
#26FUSION PROTEIN TARGETING PD-L1 AND NEUTRALIZING GAS6 AND USES THEREOF
#27NOVEL EXOSOME-BASED ANTICANCER AGENT
#28BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS
#29ANTI-KIT ANTIBODIES AND USES THEREOF
#30NOVEL CELL LINES, METHODS OF PRODUCING NATURAL KILLER CELLS AND USES THEREOF
#31NANOPORE TWEEZER APPROACH FOR PROTEIN KINASE ALLOSTERIC DRUG SCREENING
#32Cancer Stem Cell Targeted Cancer Vaccines
#33Ocular Compositions and Methods Thereof
#34COMPOSITIONS AND METHODS FOR ALLOGENEIC TRANSPLANTATION
#35Methods of treating cholangiocarcinoma
#36CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELLS (CAR-DCS) AND METHODS OF MAKING AND USING SAME
#37FUSION PROTEINS AND METHODS THEREOF
#38C-KIT antibodies and method for treating cancer with such
#39RECEPTOR TYROSINE KINASE BIOMARKERS
#40CHIMERIC RECEPTORS TO FLT3 AND METHODS OF USE THEREOF
#41COMPOSITIONS AND METHODS FOR MICROGLIA REPLACEMENT THERAPY
#42CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF
#43Crenolanib for treating FLT3 mutated proliferative disorders
#44CHIMERIC RECEPTOR SENSORS
#45METHODS OF USING FLT3L-Fc FUSION PROTEINS
#46TRANSGENE GENETIC TAGS AND METHODS OF USE
#47DEFINED COMPOSITION GENE MODIFIED T-CELL PRODUCTS
#48NON-HUMAN ANIMALS COMPRISING A HUMANIZED TRKB LOCUS
#49METHODS AND COMPOSITIONS FOR TREATING CANCER
#50REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS
#51HETEROARYL COMPOUNDS AND USES THEREOF
#52COMPOSITIONS DERIVED FROM HUMAN AMNION CELLS & RELATED METHODS
#53EGFR AND ROS1 KINASE IN CANCER
#54Exosome-based anticancer agent
#55Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy
#56Method of treating aging-associated cognitive impairment by reducing CCR3
#57Bruton's Tyrosine Kinase as Anti-Cancer Drug Target
#58Neoantigen peptide mimics
#59CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3)
#60COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 21 INSERTIONS
#61NGF Antagonists for Medical Use
#62NUCLEIC ACID CONSTRUCT ENCODING Trk FRAGMENT AND USE THEREOF
#63ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS
#64TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS
#65Expression of novel cell tags
#66Drug regulated transgene expression
#67Truncated Epiderimal Growth Factor Receptor (EGFRt) for Transduced T Cell Selection
#68Anti-kit antibodies and uses thereof
#69NOVEL ALK AND NTRK1 FUSION MOLECULES AND USES THEREOF
#70Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
#71METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
#72Expression of novel cell tags
#73Methods of treating cholangiocarcinoma
#74Anti-TrkB agonist antibodies binding to D1 domain of TrkB
#75Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method
#76Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection
#77Cancer stem cell targeted cancer vaccines
#78Vaccines against an oncogenic isoform of HER2 (ErbB2) and methods of using the same
#79VACCINES AGAINST AN ONCOGENIC ISOFORM OF ESR1 AND METHODS OF USING THE SAME
#80Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
#81Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
#82Fully stabilized asymmetric siRNA
#83Transgene genetic tags and methods of use
#84Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)
#85Crenolanib for treating FLT3 mutated proliferative disorders
#86Using nucleic acids encoding NAP-2 polypeptides to improve cardiac function
#87Activation of APC in immunotherapy
#88ROR1 antibody compositions and related methods
#89METHODS OF TREATING METASTATIC CANCERS USING AXL DECOY RECEPTORS
#90Method for treating cancer with c-kit antibodies
#91METHODS AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS
#92SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS
#93CONJUGATE VACCINE USING TRIMMING FUNCTION OF ERAP1
#94Ligand binding molecules and uses thereof
#95Exosome-based anticancer agent
#96TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMA
#97Cell
#98Anti-TrkB agonist antibodies binding to D5 domain of TrkB and methods of promoting neuronal survival in motor neuron injury, stroke or glaucoma
#99Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#100Heteroaryl compounds and uses thereof
#101FGFR GATEKEEPER MUTANT GENE AND DRUG TARGETING SAME
#102Treatment for age-related macular degeneration (AMD) and pathogenic ocular neovascularization
#103Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
#104Drug regulated transgene expression
#105Nucleic acid encoding angiopoietin-2 specific Tie2 receptor
#106Fusion proteins and methods thereof
#107Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
#108Crenolanib for treating FLT3 mutated proliferative disorders
#109Methods of detecting DDR2 mutations
#110Genetically modified rat comprising a humanized locus
#111Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
#112Methods of treating by administering anti-kit antibodies
#113MIC-1 receptor and uses thereof
#114CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME
#115Expression of novel cell tags
#116ALK and NTRK1 fusion molecules and uses thereof
#117UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof
#118Vaccines against an oncogenic isoform of HER2 (ErbB2) and methods of using the same
#119ROR1 antibody compositions and related methods
#120Vaccines against an oncogenic isoform of ESR1 and methods of using the same
#121MANUFACTURING DEVICE AND METHOD OF AN IMMUNOTHERAPEUTIC FORMULATION COMPRISING A RECOMBINANT LISTERIA STRAIN
#122TREATMENT OF OCULAR NEOVASCULARIZATION USING ANTI-VEGF PROTEINS
#123Substituted indazole derivatives active as kinase inhibitiors
#124Gene Expression Cassette And Product Thereof
#125Compositions and Methods for the Diagnosis of Retinal Neovascularization
#126Genetically engineered drug resistant T cells and methods of using the same
#127CHEMICAL SYNTHESIS
#128NAP-2 polypeptides and methods for modulating immune system activity in heart tissue
#129Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#130SRM Assay to Indicate Cancer Therapy
#131MODULATION OF AXL RECEPTOR ACTIVITY IN COMBINATION WITH CYTOREDUCTIVE THERAPY
#132Protein standard compositions and methods of making and using the same
#133Treatment of ocular neovascularization using anti-VEGF proteins
#134Receptor tyrosine kinase biomarkers
#135CSF1 THERAPEUTICS
#136METHOD FOR TREATING TAU PROTEIN-MEDIATED DEGENERATIVE NEURONAL DISEASE
#137Immunogenic Fusion Proteins For The Treatment Of Cancer
#138Antifibrotic activity of GAS6 inhibitor
#139Synergistic cancer treatment
#140Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
#141Heteroaryl compounds and uses thereof
#142Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#143Crenolanib for treating FLT3 mutated proliferative disorders
#144Method and compositions for cellular immunotherapy
#145MULTILAMELLAR LIPID VESICLE COMPOSITIONS INCLUDING A CONJUGATED ANAPLASTIC LYMPHOMA KINASE (ALK) VARIANT AND USES THEREOF
#146FULLY STABILIZED ASYMMETRIC SIRNA
#147Ligand binding molecules and uses thereof
#148Bruton's tyrosine kinase as anti-cancer drug target
#149Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)
#150METHOD FOR SCREENING COMPOUND SPECIFICALLY SUPPRESSING FORMATION OF CAVEOLAE OF CANCER CELLS, SCREENING KIT, VECTOR AND TRANSFORMANT TO BE USED IN KIT, AND METHOD FOR SELECTING PATIENT FOR WHOM MOLECULARLY TARGETED DRUG IS INDICATED
#151BIOMARKER FOR DIAGNOSIS OF AGING OR AMYOTROPHIA
#152BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 FOR USE IN THE TREATMENT OF OVARIAN CANCER
#153Transgene genetic tags and methods of use
#154Methods of detecting DDR2 mutations
#155Methods for generating engineered enzymes
#156METHOD FOR EVALUATING QUALITY OF HUMAN MESENCHYMAL STEM CELL, AND MONOCLONAL ANTIBODY FOR USE IN SAID METHOD
#157VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME
#158VACCINES AGAINST AN ONCOGENIC ISOFORM OF ESR1 AND METHODS OF USING THE SAME
#159Ocular Compositions and Methods Thereof
#160Bruton's tyrosine kinase as anti-cancer drug target
#161Tyrosine kinase biosensors and methods of use
#162Bicyclic pyrazolone compounds and methods of use
#163Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#164Methods of treating a kit-associated cancer by administering anti-kit antibodies
#165Immunogenic Polypeptide Composed of HLA-B7 Restricted Tumor Antigen-Derived Optimized Cryptic Peptides, and Uses Thereof
#166Drug regulated transgene expression
#167Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)
#168Lipid vesicle compositions and methods of use
#169Method for detecting protein modifications using specific antibodies
#170COMPOSITION FOR ACCELERATING PENETRATION THROUGH SKIN, PREPARATION FOR TRANSDERMAL ADMINISTRATION, AND SKIN PATCH PREPARATION
#171Methods of treating non-small cell lung carcinoma (NSCLC)
#172Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereof
#173OPTICALLY ACTIVATED RECEPTORS
#174Immunogenic fusion proteins for the treatment of cancer
#175COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
#176NOVEL FUSION GENES AS FACTORS RESPONSIBLE FOR GASTRIC CANCER
#177FGFR gatekeeper mutant gene and drug targeting same
#178Substituted indazole derivatives active as kinase inhibitiors
#179Substituted indazole derivatives active as kinase inhibitiors
#180Crenolanib for treating FLT3 mutated proliferative disorders
#181Methods and Kits for Detecting Prostate Cancer Biomarkers
#182NOVEL CHIMERIC GENE ATF7IP-PDGFRB OF ACUTE LYMPHOBLASTIC LEUKEMIA
#183Heteroaryl compounds and uses thereof
#184Translocation and mutant ROS kinase in human non-small cell lung carcinoma
#185CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME
#186Antiviral activity of Gas6 inhibitor
#187Using nucleic acids encoding NAP-2 and TGF-alpha polypeptides to improve cardiac function
#188Anaplastic Lymphoma Kinase (ALK) As An Oncogene Capable Of Transforming Normal Human Cells
#189Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
#190Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
#191Methods and systems for predicting misfolded protein epitopes
#192Fusion proteins and methods thereof
#193Inhibition of AXL Signaling in Anti-Metastatic Therapy
#194Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
#195ANTI-CD19 COMPOSITIONS AND METHODS FOR TREATING CANCER
#196Bruton's tyrosine kinase as anti-cancer drug target
#197Conjugate vaccine using trimming function of ERAP1
#198CSF1 THERAPEUTICS
#199Compounds and methods for producing a conjugate
#200USE OF ANTI-ERBB2 VACCINES IN ASSOCIATION WITH AN ELECTRIC FIELD
#201Lipid vesicle compositions and methods of use
#202Glycosylated VEGF decoy receptor fusion protein
#203Method of treating eye disease using glycosylated VEGF decoy receptor fusion protein
#204Artificial synthetic cDNA and method for detecting secondary glioblastoma
#205FAM150A, FAM150B, AND FAM150 ANTAGONISTS AND USES THEREOF
#206HER2/Neu cancer vaccine
#207FUSION POLYNUCLEOTIDES AND FUSION POLYPEPTIDES ASSOCIATED WITH CANCER AND PARTICULARLY MELANOMA AND THEIR USES AS THERAPEUTIC AND DIAGNOSTIC TARGETS
#208VEGFR-3 ligand binding molecules and uses thereof
#209SRM assay to indicate cancer therapy
#210Methods of treating cholangiocarcinoma
#211Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
#212UV Associated mtDNA Fusion Transcripts and Methods and Uses Thereof
#213Angiopoietin-2 specific TIE2 receptor
#214Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
#215Inhibition of AXL Signaling in Primary Tumor Therapy
#216Compositions and Methods for the Diagnosis of Retinal Neovascularization
#217Broad spectrum ErBB ligand binding molecules and methods for preparing and using them
#218Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination
#219FUSION PROTEIN FOR ACTIVATING RTK SIGNAL TRANSMISSION BY MEANS OF LIGHT, AND USE THEREOF
#220Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
#221FUSION PROTEINS AND METHODS THEREOF
#222α/β-peptide mimics of Z-domain peptides
#223FGFR2 FUSION GENE
#224AXL TYROSINE KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME
#225Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
#226FUSION GENE OF CEP55 GENE AND RET GENE
#227Cancer stem cell targeted cancer vaccines
#228BROAD SPECTRUM ERBB LIGAND BINDING MOLECULES AND METHODS FOR THEIR USE
#229Treatment of ocular neovascularization using anti-VEGF proteins
#230ALK and NTRK1 fusion molecules and uses thereof
#231Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain
#232Bruton's tyrosine kinase as anti-cancer drug target
#233METHODS OF SUPPRESSING CANCER, INCREASING WEIGHT LOSS AND/OR INCREASING INSULIN SENSITIVITY
#234Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
#235Broad spectrum ErbB ligand binding molecules and methods for preparing and using them
#236Novel Kinase Inhibition Models and Their Uses
#237Methods of treating cancer by administering an Axl ligand-binding portion of an Axl tyrosine kinase receptor extracellular domain
#238Lipid vesicle compositions and methods of use
#239Bruton's tyrosine kinase as anti-cancer drug target
#240Inhibition of SYK kinase expression
#241METHODS AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS
#242Tyrosine kinase receptor TYRO3 as a therapeutic target in the treatment of cancer
#243Gene defects and mutant ALK kinase in human solid tumors
#244Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
#245Methods of chemotype evolution
#246Gene defects and mutant ALK kinase in human solid tumors
#247METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND OTHER ANGIOGENESIS-RELATED DISEASES
#248Axl fusion proteins as Axl tyrosine kinase inhibitors
#249ZAP-70 as predictor and modulator of effector function of T cells
#250Gene defects and mutant ALK kinase in human solid tumors
#251Methods of screening for neoplastic disease states
#252BRUTON'S TYROSINE KINASE AS ANTI-CANCER DRUG TARGET
#253METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
#254Translocation and mutant ROS kinase in human non-small cell lung carcinoma
#255Use of inhibitors and antisense oligonucleotides of BTK for treating proliferative mastocytosis
#256COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID
#257Gene defects and mutant ALK kinase in human solid tumors
#258Human Ron-related gene variant associated with cancers
#259Human Ron-related gene variant associated with cancers
#260Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination
#261Delivery of siRNA by neutral lipid compositions
#262FC gamma RIIA-specific nucleic acid interference
#263METHODS AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS
#264Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
#265Human Ron-related gene variant associated with cancers
#266Inhibition of Syk kinase expression
#267Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
#268Syk-targeted nucleic acid interference
#269FcγRIIA-specific nucleic acid interference
#270Crystal structure of FMS-like tyrosine kinase
#271Inhibition of Syk kinase expression
#272siRNA libraries optimized for predetermined protein families